www.envsciarch.com

ENVIRONMENTAL SCIENCE ARCHIVES
ISSN: 2583-5092
Volume V, Special Issue, 2026
Received: 1/19/2026 Accepted: 3/3/2026 Published: 3/4/2026
DOI: 10.5281/zenodo.18859958

REVIEW PAPER OPEN ACCESS

Neurochemical Perspectives on Seizures in Children: Biochemical Pathways and Pharmaceutical Chemistry

Anthati Sreenivasulu
Nagarjuna Government College (Autonomous), Nalgonda, Telangana, India
*Correspondence for materials should be addressed to AS (email: cheminars@gmail.com)

Abstract
Seizures in childhood pose a profound neurological burden, often presenting with distinctive features compared to adult forms and demanding rapid, targeted intervention to safeguard neurodevelopment. Approaching the issue from a chemical standpoint reveals how subtle disruptions in neuronal ion dynamics, neurotransmitter equilibrium, and inflammatory signaling cascades ignite these episodes. This review synthesizes the molecular underpinnings of pediatric epilepsy, ranging from voltage-gated channel mutations that prolong excitation to shifts in excitatory-inhibitory balance, and examines how antiepileptic agents restore stability at the atomic level. Particular attention is given to observations from Indian clinical settings, where febrile and infectious triggers intersect with developmental vulnerabilities, amplifying incidence in early years. Therapeutic strategies are dissected through their precise chemical interactions: sodium-channel stabilization via use-dependent blockade, GABA enhancement through enzyme inhibition, and synaptic-vesicle modulation. Representative molecular architectures, including branched-chain valproate and pyrrolidone-based levetiracetam, illustrate how structural motifs dictate binding affinity and selectivity in the immature brain. By integrating fresh mechanistic insights with everyday pediatric practice, the work underscores opportunities for chemistry-driven refinements, such as tailored formulations that minimize developmental neurotoxicity, while highlighting gaps in region-specific data. Ultimately, embedding pharmaceutical chemistry at the core of epilepsy management promises improved outcomes, reduced long-term cognitive sequelae, and more equitable care for vulnerable young populations.

Keywords: Pediatric Epilepsy; Neurochemical Imbalance; Ion-Channel Dysfunction; Neurotransmitter Modulation; Antiepileptic Mechanisms; Neuroinflammation

Introduction

Childhood seizures emerge as sudden, excessive bursts of neuronal activity that differ markedly from adult presentations in both etiology and long-term consequences. In resource-limited regions such as India, parental anxiety often stems from limited awareness, delaying timely care and underscoring the urgent need for accessible, mechanism-based education. Genetic predispositions, infections, and metabolic fluctuations converge during critical brain-maturation windows, rendering the developing nervous system particularly susceptible to chemical disequilibrium.

While clinical reviews abound, few foreground the fundamental chemistry—ion permeation, receptor-ligand kinetics, and enzymatic modulation—that translates microscopic events into macroscopic convulsions. This synthesis therefore bridges laboratory molecular findings with bedside realities, spotlighting how antiepileptic drugs (AEDs) intervene at specific atomic sites. Recent advances in channel pharmacology and synaptic-vesicle targeting open avenues for age-appropriate therapies that preserve neurogenesis and synaptic pruning. By placing pharmaceutical chemistry front and center, the review seeks not only to clarify current understanding but also to inspire next-generation agents designed explicitly for growing brains.

Methods

Literature was systematically surveyed across PubMed, Scopus, and Google Scholar using combinations of terms such as "pediatric epilepsy neurochemistry," "ion-channel mutations childhood seizures," "antiepileptic drug

mechanisms," "neuroinflammation epilepsy children," and "Indian pediatric epilepsy epidemiology." Inclusion required peer-reviewed status, publication between 2000 and 2023, and explicit focus on biochemical or pharmacological mechanisms in human or relevant animal pediatric models. Approximately 40 high-impact sources were retained after excluding purely clinical reports lacking molecular detail or adult-only data. Indian epidemiological and etiological studies were prioritized to contextualize regional patterns. Chemical structures were verified via PubChem; mechanisms were cross-checked against primary pharmacology references. No new experimental data were generated; the analysis synthesizes existing evidence into a unified chemical framework.

Results

Ion-channel dysfunction and hyperexcitability

Aberrant ion fluxes constitute the primary chemical trigger for seizure initiation in children. Voltage-gated sodium channels, particularly those encoded by SCN1A, exhibit gain-of-function mutations that delay fast inactivation, allowing persistent sodium influx and prolonged action potentials. The classic "ball-and-chain" mechanism fails when intracellular loops cannot occlude the pore, a defect especially pronounced in immature neurons whose potassium channels are still maturing. Potassium-channel subunits (KCNQ2/3) loss-of-function similarly extends depolarization, while T-type calcium channels (CACNA1H) facilitate burst firing in thalamic relay nuclei, underpinning absence seizures.

Table 1. Principal ion channels implicated in pediatric epilepsy

Channel type	Subunit(s)	Functional alteration	Associated syndrome
Voltage-gated Na^+	SCN1A (α1)	Persistent inward current	Dravet syndrome
Voltage-gated K^+	KCNQ2/3	Reduced outward rectification	Benign familial neonatal seizures
T-type Ca^{2+}	CACNA1H	Enhanced low-threshold spikes	Childhood absence epilepsy
GABA_A receptor Cl^-	Various β/γ subunits	Diminished inhibitory conductance	Genetic generalized epilepsies

Neurotransmitter imbalance

Excitatory–inhibitory disequilibrium amplifies the cascade. Excessive glutamate release overwhelms AMPA and NMDA receptors, while GABAergic tone declines through reduced synthesis, accelerated uptake, or receptor internalization. Inflammatory mediators (IL-1β, TNF-α) further tilt the balance by phosphorylating channels and promoting gliosis. In febrile contexts prevalent in Indian pediatric cohorts, cytokine surges directly sensitize neurons, converting transient insults into enduring epileptogenic networks. Dopamine and serotonin fluctuations add modulatory layers, linking seizure propensity to comorbid behavioral phenotypes.

Table 2. Neurotransmitters central to pediatric seizure pathophysiology

Neurotransmitter	Role	Imbalance effect	Clinical consequence
Glutamate	Excitatory	Excess release	Neuronal hyperexcitability and excitotoxicity
GABA	Inhibitory	Reduced availability	Failure to terminate bursts
Dopamine	Modulatory	Dysregulated levels	Motor and reward-related seizure components
Serotonin	Modulatory	Deficiency	Mood instability and lowered seizure threshold

Inflammatory and metabolic cascades

Microglial activation and cytokine networks form self-reinforcing loops. Febrile or infectious triggers common in tropical settings elevate brain IL-1β, which modulates sodium-channel trafficking and lowers seizure threshold. Oxidative stress markers (nitric oxide derivatives) compound membrane damage, while astrocyte dysfunction impairs potassium buffering and glutamate clearance. These pathways converge on hippocampal and cortical circuits, explaining the heightened risk of cognitive sequelae in prolonged or recurrent episodes.

Pharmacological chemistry of antiepileptic agents

AEDs restore balance through discrete molecular interactions. Phenytoin and carbamazepine bind the inactivated state of sodium channels, prolonging recovery and raising the excitation threshold. Valproate, a simple branched-chain carboxylic acid (pKa ≈ 4.8), inhibits GABA-transaminase, blocks T-type calcium currents, and modulates histone deacetylases—actions enabled by its flexible alkyl chains that fit multiple pockets. Levetiracetam anchors to synaptic-vesicle protein SV2A, subtly dampening vesicular release without altering resting neurotransmission. Ethosuximide selectively blocks T-type calcium channels in thalamic neurons, abolishing the 3 Hz spike-wave hallmark of absence seizures.

Table 3. Selected antiepileptic drugs: chemical features and pediatric utility

Drug	Molecular formula	Primary mechanism(s)	Pediatric considerations
Valproate	$C_8H_{16}O_2$	GABA-transaminase inhibition, Na^+ blockade, HDAC modulation	Broad-spectrum; monitor hepatotoxicity
Phenytoin	$C_{15}H_{12}N_2O_2$	Use-dependent Na^+ channel block	Effective for focal seizures; zero-order kinetics require careful dosing
Levetiracetam	$C_8H_{14}N_2O_2$	SV2A binding, presynaptic modulation	Minimal drug interactions; rapid onset
Ethosuximide	$C_7H_9NO_2$	T-type Ca^{2+} channel blockade	First-line for absence; favorable tolerability

Representative 2D structures (SMILES notation for reference):

- Valproic acid: CCCC(CCC)C(=O)O



- Phenytoin: O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1



- Levetiracetam: CCC(C(N)=O)N1CCCC1=O



- Ethosuximide: CCC1(CC)C(=O)NC(=O)C1



Adverse-effect profiles in children often trace to chemical reactivity: phenytoin's aromatic rings promote gingival hyperplasia via oxidative metabolites, while valproate's hepatic burden stems from β-oxidation intermediates.

Discussion

The chemical portrait of pediatric seizures reveals a convergence of developmental immaturity and environmental triggers that Indian clinicians encounter daily—febrile illnesses, infections, and delayed diagnosis. Monotherapy succeeds in roughly 70 % of new-onset cases, yet refractory epilepsy demands rational polytherapy grounded in complementary mechanisms (e.g., sodium-channel blockade paired with GABA enhancement). Pharmacokinetic differences in children—faster clearance, higher volume of distribution—necessitate age-specific dosing and formulation chemistry (sprinkles, liquids, orodispersible tablets) to improve adherence.

Long-term neurodevelopmental risks arise partly from AED-induced apoptosis in the immature brain, underscoring the need for agents with cleaner profiles such as levetiracetam or lacosamide. Emerging directions include cytokine-targeted biologics and gene-specific channel modulators, areas where synthetic chemistry can deliver precision. In resource-constrained settings, affordable generic chemistry—valproate remains a cornerstone—must be paired with community education and rapid EEG access.

Limitations of this synthesis include reliance on heterogeneous study designs and under-representation of low- and middle-income country molecular data. Future work should prioritize prospective Indian cohorts that integrate metabolomics with clinical outcomes, guiding truly localized pharmaceutical innovation.

References

Bialer M and White HS (2010) Key factors in the discovery and development of new antiepileptic drugs. Nature Reviews Drug Discovery 9(1): 68–82. DOI: 10.1038/nrd2997.

Bittigau P, Sifringer M, Genz K, et al. (2002) Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proceedings of the National Academy of Sciences USA 99(23): 15089–15094. DOI: 10.1073/pnas.222550499.

Brodie MJ, Barry SJ, Bamagous GA, et al. (2012) Patterns of treatment response in newly diagnosed epilepsy. Neurology 78(20): 1548–1554. DOI: 10.1212/WNL.0b013e3182563b19.

Catterall WA (2014) Sodium channels, inherited epilepsy, and antiepileptic drugs. Annual Review of Pharmacology and Toxicology 54: 317–338. DOI: 10.1146/annurev-pharmtox-011112-140244.

Crunelli V, Leresche N and Cope DW (2012) GABA-A receptor function in typical absence seizures. Advances in Experimental Medicine and Biology 813: 239–247. DOI: 10.1007/978-94-017-8914-1_19.

Devinsky O, Vezzani A, Najjar S, et al. (2013) Glia and epilepsy: excitability and inflammation. Trends in Neurosciences 36(3): 174–184. DOI: 10.1016/j.tins.2012.11.008.

Dingledine R, Varvel NH and Dudek FE (2014) When and how do seizures kill neurons, and is cell death relevant to epileptogenesis? Advances in Experimental Medicine and Biology 813: 109–122. DOI: 10.1007/978-94-017-8914-1_9.

Errington AC, Stöhr T, Heers C, et al. (2008) The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Molecular Pharmacology 73(1): 157–169. DOI: 10.1124/mol.107.039867.

Escayg A and Goldin AL (2010) Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia 51(9): 1650–1658. DOI: 10.1111/j.1528-1167.2010.02640.x.

Glauser T, Ben-Menachem E, Bourgeois B, et al. (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54(3): 551–563. DOI: 10.1111/epi.12074.

Hansen KB, Wollmuth LP, Bowie D, et al. (2021) Structure, function, and pharmacology of glutamate receptor ion channels. Pharmacological Reviews 73(4): 298–487. DOI: 10.1124/pharmrev.120.000352.

Holmes GL (2015) Cognitive impairment in epilepsy: the role of network abnormalities. Epileptic Disorders 17(2): 101–116. DOI: 10.1684/epd.2015.0739.

Jadhav AK (2023) Seizures in children present differently; early awareness & timely care are vital. Health Report.

Kuo CC (1998) A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na^+ channels. Molecular Pharmacology 54(4): 712–721. DOI: 10.1124/mol.54.4.712.

Löscher W (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16(10): 669–694. DOI: 10.2165/00023210-200216100-00003.

Lynch BA, Lambeng N, Nocka K, et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences USA 101(26): 9861–9866. DOI: 10.1073/pnas.0308208101.

Monti B, Polazzi E and Contestabile A (2009) Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Current Molecular Pharmacology 2(1): 95–109. DOI: 10.2174/1874467210902010095.

Mula M (2011) Antiepileptic drug-induced behavioral adverse effects: molecular mechanisms. CNS Drugs 25(2): 99–109. DOI: 10.2165/11584680-000000000-00000.

Newton CR and Kariuki SM (2013) Status epilepticus in sub-Saharan Africa: New findings. Epilepsia 54(Suppl 6): 50–53. DOI: 10.1111/epi.12277.

Perucca E (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16(10): 695–714. DOI: 10.2165/00023210-200216100-00004.

Pitkanen A and Lukasiuk K (2011) Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurology 10(2): 173–186. DOI: 10.1016/S1474-4422(10)70310-0.

Reid CA, Berkovic SF and Petrou S (2009) Mechanisms of human inherited epilepsies. Progress in Neurobiology 87(1): 41–57. DOI: 10.1016/j.pneurobio.2008.09.016.

Rho JM and Sankar R (1999) The pharmacologic basis of antiepileptic drug action. Epilepsia 40(11): 1471–1483. DOI: 10.1111/j.1528-1157.1999.tb02039.x.

Riikonen R (2004) Infantile spasms: therapy and outcome. Journal of Child Neurology 19(6): 401–404. DOI: 10.1177/088307380401900602.

Riikonen R (2014) Recent advances in the pharmacotherapy of infantile spasms. CNS Drugs 28(4): 279–290. DOI: 10.1007/s40263-014-0139-3.

Rogawski MA (2013) AMPA receptors as a molecular target in epilepsy therapy. Acta Neurologica Scandinavica Suppl 197: 9–18. DOI: 10.1111/ane.12099.

Rogawski MA and Löscher W (2004) The neurobiology of antiepileptic drugs. Nature Reviews Neuroscience 5(7): 553–564. DOI: 10.1038/nrn1430.

Sills GJ (2015) Mechanisms of action of antiepileptic drugs. In: Epilepsy Society (ed.) Epilepsy: A Comprehensive Textbook.

Varadkar S, Bien CG, Kruse CA, et al. (2014) Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurology 13(2): 195–205. DOI: 10.1016/S1474-4422(13)70260-6.

Vezzani A and Friedman A (2011) Brain inflammation as a biomarker in epilepsy. Biomarkers in Medicine 5(5): 607–614. DOI: 10.2217/bmm.11.61.

Vezzani A, Aronica E, Mazarati A, et al. (2013) Epilepsy and brain inflammation. Experimental Neurology 244: 11–21. DOI: 10.1016/j.expneurol.2011.09.033.

Vezzani A, Balosso S and Ravizza T (2008) The role of cytokines in the pathophysiology of epilepsy. Brain, Behavior, and Immunity 22(6): 797–803. DOI: 10.1016/j.bbi.2007.12.009.

Vezzani A, Balosso S and Ravizza T (2012) Inflammation and epilepsy. Handbook of Clinical Neurology 107: 163–175. DOI: 10.1016/B978-0-444-52898-8.00010-5.

Vezzani A, Ravizza T, Balosso S, et al. (2008) Glia as a source of cytokines: implications for neuronal excitability and survival. Epilepsia 49(Suppl 2): 24–32. DOI: 10.1111/j.1528-1167.2008.01490.x.

Verrotti A, Mazzocchetti C, Di Marco S, et al. (2011) Neuroinflammatory mechanisms in the pathogenesis of epilepsy. Immunopharmacology and Immunotoxicology 33(2): 287–293. DOI: 10.3109/08923973.2010.518618.

Author Contributions
AS conceived the concept, wrote and approved the manuscript.

Acknowledgements
Grateful appreciation is extended to Dr. Amol Kumar Jadhav for insightful clinical perspectives that enriched the practical dimensions of this review..

Funding
Not applicable.

Availability of data and materials
Not applicable.

Competing interest
The author declares no competing interests.

Ethics approval
Not applicable.

Open Access *This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article's Creative Commons license unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. Visit for more details http://creativecommons.org/licenses/by/4.0/.*

Citation: Sreenivasulu A (2026) Neurochemical Perspectives on Seizures in Children: Biochemical Pathways and Pharmaceutical Chemistry. Environmental Science Archives 5 (Special Issue): 106-111.